Literature DB >> 17967913

Human immunodeficiency virus types 1 and 2 exhibit comparable sensitivities to Zidovudine and other nucleoside analog inhibitors in vitro.

Robert A Smith1, Geoffrey S Gottlieb, Donovan J Anderson, Crystal L Pyrak, Bradley D Preston.   

Abstract

Using an indicator cell assay that directly quantifies viral replication, we show that human immunodeficiency virus types 1 and 2 (HIV-1 and HIV-2, respectively) exhibit similar sensitivities to 3'-azido-3'-deoxythymidine (zidovudine) as well as other nucleoside analog inhibitors of reverse transcriptase. These data support the use of nucleoside analogs for antiviral therapy of HIV-2 infection.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17967913      PMCID： PMC2223890          DOI： 10.1128/AAC.01004-07

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  27 in total

1.  HIV-1 reverse transcription. A termination step at the center of the genome.

Authors:  P Charneau; G Mirambeau; P Roux; S Paulous; H Buc; F Clavel
Journal:  J Mol Biol       Date:  1994-09-02       Impact factor: 5.469

2.  Natural resistance of human immunodeficiency virus type 2 to zidovudine.

Authors:  Patrick Reid; Hamish MacInnes; Mian-Er Cong; Walid Heneine; J Gerardo García-Lerma
Journal:  Virology       Date:  2005-06-05       Impact factor: 3.616

3.  Catalytic properties of the reverse transcriptases of human immunodeficiency viruses type 1 and type 2.

Authors:  A Hizi; R Tal; M Shaharabany; S Loya
Journal:  J Biol Chem       Date:  1991-04-05       Impact factor: 5.157

4.  Molecular cloning of the human immunodeficiency virus subtype 2 strain HIV-2UC2.

Authors:  S W Barnett; H S Legg; Y Sun; J Klinger; D J Blackbourn; C P Locher; J A Levy
Journal:  Virology       Date:  1996-08-01       Impact factor: 3.616

5.  Multidrug-resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy.

Authors:  A K Iversen; R W Shafer; K Wehrly; M A Winters; J I Mullins; B Chesebro; T C Merigan
Journal:  J Virol       Date:  1996-02       Impact factor: 5.103

6.  Reduced rate of disease development after HIV-2 infection as compared to HIV-1.

Authors:  R Marlink; P Kanki; I Thior; K Travers; G Eisen; T Siby; I Traore; C C Hsieh; M C Dia; E H Gueye
Journal:  Science       Date:  1994-09-09       Impact factor: 47.728

7.  Susceptibility to protease inhibitors in HIV-2 primary isolates from patients failing antiretroviral therapy.

Authors:  Berta Rodés; Julie Sheldon; Carlos Toro; Victoria Jiménez; Miguel Angel Alvarez; Vincent Soriano
Journal:  J Antimicrob Chemother       Date:  2006-02-07       Impact factor: 5.790

8.  Comparison of the sensitivities of primary isolates of HIV type 2 and HIV type 1 to antiviral drugs and drug combinations.

Authors:  S W Cox; K Apéria; J Albert; B Wahren
Journal:  AIDS Res Hum Retroviruses       Date:  1994-12       Impact factor: 2.205

9.  VPX mutants of HIV-2 are infectious in established cell lines but display a severe defect in peripheral blood lymphocytes.

Authors:  M Guyader; M Emerman; L Montagnier; K Peden
Journal:  EMBO J       Date:  1989-04       Impact factor: 11.598

10.  Why do HIV-1 and HIV-2 use different pathways to develop AZT resistance?

Authors:  Paul L Boyer; Stefan G Sarafianos; Patrick K Clark; Eddy Arnold; Stephen H Hughes
Journal:  PLoS Pathog       Date:  2006-02-17       Impact factor: 6.823
View more
  19 in total

1.  Comparison of the Antiviral Activity of Bictegravir against HIV-1 and HIV-2 Isolates and Integrase Inhibitor-Resistant HIV-2 Mutants.

Authors:  Robert A Smith; Dana N Raugi; Vincent H Wu; Christopher G Zavala; Jennifer Song; Khardiata Mbaye Diallo; Moussa Seydi; Geoffrey S Gottlieb
Journal:  Antimicrob Agents Chemother       Date:  2019-04-25       Impact factor: 5.191

Review 2.  Antiretroviral drug resistance in human immunodeficiency virus type 2.

Authors:  Michel L Ntemgwa; Thomas d'Aquin Toni; Bluma G Brenner; Ricardo J Camacho; Mark A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  2009-05-26       Impact factor: 5.191

3.  Identification of a broad-spectrum antiviral small molecule against severe acute respiratory syndrome coronavirus and Ebola, Hendra, and Nipah viruses by using a novel high-throughput screening assay.

Authors:  Hatem A Elshabrawy; Jilao Fan; Christine S Haddad; Kiira Ratia; Christopher C Broder; Michael Caffrey; Bellur S Prabhakar
Journal:  J Virol       Date:  2014-02-05       Impact factor: 5.103

4.  Amino acid residues in HIV-2 reverse transcriptase that restrict the development of nucleoside analogue resistance through the excision pathway.

Authors:  Mar Álvarez; María Nevot; Jesús Mendieta; Miguel A Martínez; Luis Menéndez-Arias
Journal:  J Biol Chem       Date:  2017-12-22       Impact factor: 5.157

5.  The Nucleoside Analog BMS-986001 Shows Greater In Vitro Activity against HIV-2 than against HIV-1.

Authors:  Robert A Smith; Dana N Raugi; Vincent H Wu; Sally S Leong; Kate M Parker; Mariah K Oakes; Papa Salif Sow; Selly Ba; Moussa Seydi; Geoffrey S Gottlieb
Journal:  Antimicrob Agents Chemother       Date:  2015-09-21       Impact factor: 5.191

6.  Access of HIV-2 to CD169-dependent dendritic cell-mediated trans infection pathway is attenuated.

Authors:  Suzanne D G Kijewski; Hisashi Akiyama; Amin Feizpour; Caitlin M Miller; Nora-Guadalupe P Ramirez; Björn M Reinhard; Suryaram Gummuluru
Journal:  Virology       Date:  2016-08-11       Impact factor: 3.616

7.  Emergence of multiclass drug-resistance in HIV-2 in antiretroviral-treated individuals in Senegal: implications for HIV-2 treatment in resouce-limited West Africa.

Authors:  Geoffrey S Gottlieb; Ndeye Mery Dia Badiane; Stephen E Hawes; Louise Fortes; Macoumba Toure; Cheikh T Ndour; Alison K Starling; Fatou Traore; Fatima Sall; Kim G Wong; Stephen L Cherne; Donovan J Anderson; Stefanie A Dye; Robert A Smith; James I Mullins; Nancy B Kiviat; Papa Salif Sow
Journal:  Clin Infect Dis       Date:  2009-02-15       Impact factor: 9.079

8.  Antiretroviral drug resistance in HIV-2: three amino acid changes are sufficient for classwide nucleoside analogue resistance.

Authors:  Robert A Smith; Donovan J Anderson; Crystal L Pyrak; Bradley D Preston; Geoffrey S Gottlieb
Journal:  J Infect Dis       Date:  2009-05-01       Impact factor: 5.226

9.  HIV type 2 protease, reverse transcriptase, and envelope viral variation in the PBMC and genital tract of ARV-naive women in Senegal.

Authors:  Geoffrey S Gottlieb; Stephen E Hawes; Kim G Wong; Dana N Raugi; Habibatou D Agne; Cathy W Critchlow; Nancy B Kiviat; Papa Salif Sow
Journal:  AIDS Res Hum Retroviruses       Date:  2008-06       Impact factor: 2.205

10.  Novel inhibitors of human immunodeficiency virus type 2 infectivity.

Authors:  Lauren B Beach; Jonathan M Rawson; Baek Kim; Steven E Patterson; Louis M Mansky
Journal:  J Gen Virol       Date:  2014-08-07       Impact factor: 3.891
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.